Mendus AB (Sweden) Insiders
| IMMU Stock | SEK 8.15 0.03 0.37% |
Mendus AB employs about 31 people. The company is managed by 7 executives with a total tenure of roughly 73 years, averaging almost 10.0 years of service per executive, having 4.43 employees per reported executive. Breaking down Mendus AB's management performance can provide insight into the firm performance.
| MD MBA Insider Bus Advisor |
| Leopold Bertea Insider Chief Officer |
Mendus |
Mendus AB Management Team Effectiveness
The company has return on total asset (ROA) of (0.1114) % which means that it has lost $0.1114 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2053) %, meaning that it generated substantial loss on money invested by shareholders. Mendus AB's management efficiency ratios could be used to measure how well Mendus AB manages its routine affairs as well as how well it operates its assets and liabilities.Mendus AB Workforce Comparison
Mendus AB is rated second overall in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 316. Mendus AB holds roughly 31.0 in number of employees claiming about 10% of stocks in Biotechnology industry.
Mendus AB Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Mendus AB Price Series Summation is a cross summation of Mendus AB price series and its benchmark/peer.
Mendus AB Notable Stakeholders
A Mendus AB stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Mendus AB often face trade-offs trying to please all of them. Mendus AB's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Mendus AB's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| MD MBA | Bus Advisor | Profile | |
| Leopold Bertea | Chief Officer | Profile | |
| Lotta Ferm | Chief Officer | Profile | |
| Erik Manting | Chief Officer | Profile | |
| Jeroen MD | Chief Officer | Profile | |
| PerOlof Gunnesson | Advisor Contracts | Profile | |
| Alex MD | CoFounder Officer | Profile |
About Mendus AB Management Performance
The success or failure of an entity such as Mendus AB often depends on how effective the management is. Mendus AB management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Mendus management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Mendus management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Its lead product is ilixadencel, which is in Phase II clinical trial for the treatment of kidney cancer and Phase IbII clinical trials for the treatment of head and neck cancer, non-small cell lung cancer, and gastric cancer, as well as is in a Phase III clinical trials to treat liver cancer and gastrointestinal stromal tumors. Immunicum AB has a collaboration agreement with Merck KGaA and Pfizer Inc. to evaluate ilixadencel in combination with avelumab in multi-indication Phase IbII study. Immunicum is traded on Stockholm Stock Exchange in Sweden.
Please note, the imprecision that can be found in Mendus AB's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Mendus AB. Check Mendus AB's Beneish M Score to see the likelihood of Mendus AB's management manipulating its earnings.
Mendus AB Workforce Analysis
Traditionally, organizations such as Mendus AB use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Mendus AB within its industry.Mendus AB Manpower Efficiency
Return on Mendus AB Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 4.2M | |
| Net Loss Per Executive | 18.6M | |
| Working Capital Per Employee | 1.2M | |
| Working Capital Per Executive | 5.1M |
Additional Tools for Mendus Stock Analysis
When running Mendus AB's price analysis, check to measure Mendus AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mendus AB is operating at the current time. Most of Mendus AB's value examination focuses on studying past and present price action to predict the probability of Mendus AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mendus AB's price. Additionally, you may evaluate how the addition of Mendus AB to your portfolios can decrease your overall portfolio volatility.